The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models.
Nathan M KendserskyJarrett LindsayE Anders KolbMalcolm A SmithBeverly A TeicherStephen W EricksonEric Jay EarleyYael P MosseDaniel MartinezJennifer PogorilerKateryna KrytskaKhushbu PatelDavid GroffMatthew TsangSamson GhiluYifei WangSteven SeamanYang FengBrad St CroixRichard G GorlickRaushan T KurmashevaPeter J HoughtonJohn M MarisPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
m276-SL-PBD has significant antitumor activity across a broad panel of pediatric solid tumor PDX models.